Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway

Melanoma is the most aggressive type of skin cancer with a high incidence and low survival rate. More than half of melanomas present the activating BRAF mutations, along which V600E mutant represents 70%–90%. Vemurafenib (Vem) is an FDA-approved small-molecule kinase inhibitor that selectively targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Otkur, Wuxiyar, Wang, Aman, Wang, Wen, Lyu, Yitong, Fang, Lei, Shan, Xiu, Song, Mingzhou, Feng, Yan, Zhao, Yi, Piao, Hai-Long, Qi, Huan, Liu, Ji-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411668/
https://www.ncbi.nlm.nih.gov/pubmed/36034784
http://dx.doi.org/10.3389/fphar.2022.906043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411668/
https://www.ncbi.nlm.nih.gov/pubmed/36034784
http://dx.doi.org/10.3389/fphar.2022.906043

Ejemplares similares